We are live on ! Find out more
SONN

Sonnet BioTherapeutics
SONN

Delisted

SONN was delisted on the 2nd of December, 2025.

Back to rankings

21 hedge funds and large institutions have $2.11M invested in Sonnet BioTherapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

31% more funds holding

Funds holding: 16 → 21 (+5)

0.08% less ownership

Funds ownership: 0.21% → 0.12% (-0.08%)

20% less capital invested

Capital invested by funds: $2.63M → $2.11M (-$525K)

Holders
21
Holders Change
+5
Holders Change %
+31.25%
% of All Funds
0.33%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
6
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$832K
2
Renaissance Technologies
Renaissance Technologies
New York
+$111K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$56.3K
4
State Street
State Street
Massachusetts
+$37.9K
5
VF
Virtu Financial
New York
+$34.7K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$634K
2
Walleye Capital
Walleye Capital
New York
-$599K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$343K
4
AC
Ayrton Capital
Connecticut
-$276K
5
CH
CVI Holdings
Delaware
-$253K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$1.61M +$832K +11,793 +171%
Renaissance Technologies
2
Renaissance Technologies
New York
$144K +$111K +1,578 +1,715%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$83K +$56.3K +798 +487%
State Street
4
State Street
Massachusetts
$46.3K +$37.9K +537 New
VF
5
Virtu Financial
New York
$42K +$34.7K +492 New
ASN
6
Advisory Services Network
Georgia
$35K +$24.1K +341 +525%
TSS
7
Two Sigma Securities
New York
$33.4K +$27.3K +387 New
MCG
8
McCollum Christoferson Group
New York
$19.8K +$16.2K +230 New
JP Morgan Chase
9
JP Morgan Chase
New York
$14.7K +$12K +170 New
HF
10
HRT Financial
New York
$13K +$11K +156 New
CSS
11
Cubist Systematic Strategies
Connecticut
$11.4K +$9.31K +132 New
XT
12
XTX Topco
Cayman Islands
$11K +$9.03K +128 New
Vanguard Group
13
Vanguard Group
Pennsylvania
$8.85K – – –
Northern Trust
14
Northern Trust
Illinois
$8.75K – – –
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$8.6K +$7.05K +100 New
BlackRock
16
BlackRock
New York
$6.42K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$5.53K +$2.4K +34 +113%
Morgan Stanley
18
Morgan Stanley
New York
$1.54K +$846 +12 +200%
Osaic Holdings
19
Osaic Holdings
Arizona
$490 +$423 +6 New
Wells Fargo
20
Wells Fargo
California
$92 +$71 +1 New
IA
21
IFP Advisors
Florida
$70 – – –
Fidelity Investments
22
Fidelity Investments
Massachusetts
$2 – – –
Bank of America
23
Bank of America
North Carolina
$1 – – –
AFM
24
Anson Funds Management
Texas
– -$634K -10,000 Closed
Walleye Capital
25
Walleye Capital
New York
– -$599K -9,458 Closed
1
2

SONN Hedge Fund Activity: Q2 2023 in Review

21 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2023, worth a combined $2.11M — down 20% from $2.63M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new SONN positions and 6 closed out — a net gain of 5 holders — while 6 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, adding an estimated $832K. The largest seller was Anson Funds Management, exiting entirely with an estimated $634K sold.

  • 21 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2023, up from 16 in Q1 2023.
  • Funds reported $2.11M of Sonnet BioTherapeutics stock for Q2 2023, down 20% quarter-over-quarter.
  • 11 funds opened new Sonnet BioTherapeutics positions in Q2 2023 and 6 closed out, a net change of +5 holders.
  • The largest Sonnet BioTherapeutics buyer in Q2 2023 was Sabby Management, an estimated $832K added.
  • The largest Sonnet BioTherapeutics seller in Q2 2023 was Anson Funds Management, an estimated $634K sold.

Based on aggregated 13F filings for Q2 2023.